Summary
Metachromatic Leukodystrophy (MLD) is a rare genetic disorder that affects the brain, spinal cord, and nerves. It is caused by the lack of a crucial enzyme, called arylsulfatase A (ARSA). In MLD, ARSA is dysfunctional or lacking resulting in a build of toxic lipids called sulfatides in cells within the body. Over time, this accumulation damages the protective covering around the nerve cells (myelin) resulting in progressive dysfunction of the brain and nervous system.
There are three forms of MLD based on when symptoms begin: late infantile form, juvenile form and adult form. All forms of MLD worsens over time, but the rate of symptom progression varies in each individual. Signs and symptoms can vary by subtype, but typically include problems with movement/coordination, walking, thinking, and behavior.
Description
In healthy people, ARSA breaks down sulfatides, preventing damage to the myelin. People with MLD inadequate or absent ARSA, which results in a buildup of sulfatides that can then damage the nervous system, including the brain, spinal cord and nerves. There are three main types of MLD, classified based on when symptoms start. The severity can range from rapid decline in young children to a slower course in adults. MLD can be life-threatening, especially in children, as the disease progresses and affects vital functions like swallowing and breathing.
Subtypes of MLD
MLD has been classified into three clinical forms based on age of onset:
- Late-infantile (onset < 30 months)
- Juvenile (onset 2.5-16 years old)
- Adult (onset >16 years old)
Signs and Symptoms
Symptoms vary by MLD subtype but commonly can include:
- Trouble walking or moving, often starting with difficulty lifting feet
- Muscle weakness and/or stiffness
- Problems with speech and swallowing
- Changes in thinking and behavior
- Worsening performance in school
- Difficulty with coordination
- Seizures
Common symptoms by type
Late-infantile (onset < 30 months): approximately 50% of cases
- May have developmental delay
- Progressive loss of motor skills (eg ability to sit, roll, walk)
- Difficulty with coordination or clumsiness
- Muscle weakness or stiffness
- Slurred speech or decreased speech
- Visual disturbances and abnormal eye movements
Juvenile (2.5-16yo): This type has a variable presentation
- Typically, early developmental milestones are met
- Loss of motor skills
- Cognitive decline (eg decline in school performance, difficulty completing tasks)
- Behavioral problems and personality changes (increased impulsivity, loss of inhibition)
- Muscle weakness or stiffness
- Changes in walking and gait
- Peripheral neuropathy, which may include numbness, tingling, or pain in the arms and legs
- Seizures
Adult (>16yo):
- Personality changes
- Changes in thinking and performance at school/work
- Peripheral neuropathy, which may include numbness, tingling, or pain in the arms and legs
- Seizures
- minimal or no motor findings
Causes
It is important to remember that MLD is not caused by anything a parent does. MLD is inherited in an autosomal recessive manner, meaning patients with MLD have two disease-causing variants (or genetic changes) in the arylsulfatase A gene (ARSA). These genetic changes together cause the body to produce no to low levels of arylsulfatase, an enzyme needed to breakdown toxic lipids. Rarely, MLD can be due to saposin B (SAPB) deficiency.
Laboratory Investigations
Diagnosis involves several tests:
- Genetic testing to look for changes in the ARSA gene
- Measuring for reduced activity of ARSA enzyme activity in the blood and/or skin cells
- Urine tests to check for high sulfatide levels
- MRI brain to look for changes in the white matter of the brain
- A normal MRI does not exclude MLD
Additional tests that may be helpful in MLD management:
- Nerve conduction studies to evaluate nerve dysfunction
- Neurocognitive testing to evaluate for cognitive changes
- Abdominal ultrasound to evaluate for gallbladder dysfunction
These tests along with clinical symptoms are used to confirm MLD. Most tests are done at diagnosis, but some (like MRI) may be repeated to track disease progress
Treatment and Therapies
There is no cure for MLD, but treatments can help manage symptoms and slow the disease in some cases. Options include:
- Medications to treat symptoms like seizures, muscle stiffness, and behavior problems
- Physical, occupational, and speech therapy to help with movement and communication
- Educational support and accommodations are essential for children and adolescents with MLD
- Nutritional support, including feeding tubes if swallowing becomes hard
- Stem cell or bone marrow transplants may help if done very early in patients with no or minimal symptoms
- Gene therapy may be helpful for children with no to minimal symptoms. Discuss with your doctor if this is an option for your child.
Treatment depends on the type and stage of MLD. Side effects depend on the therapy, and some treatments (like transplants and gene therapy) carry serious risks. All risks should be discussed with your treating physician.
Without treatment, the disease will get worse, leading to trouble with movement, trouble with thinking and learning, and eventually life-threatening complications.
Outlook
The outlook for people with MLD depends on the type and treatment. Late infantile MLD usually leads to severe disability and shortened life by childhood. Children with MLD will need increasing help with daily activities, learning, and self-care. Most will not be able to live independently as adults. Juvenile and adult forms progress more slowly, but most people will lose independence over time. The disorder affects family life, school/work, and social life.
Resources
The links and resources included in this section are solicited directly from the community by the Child Neurology Foundation through a formal submission process. CNF reserves the right to remove entities at any time if information is deemed inappropriate or inconsistent with the mission, vision, and values of CNF. The authors listed on this page have not endorsed the resources or links provided in this section.
United Leukodystrophy Foundation
OUR MISSION is to provide support to the leukodystrophy community and enable platforms to accelerate improving patient quality of life and finding cures.
OUR VISION is to meet the needs of patients and families, whether newly diagnosed or living with a leukodystrophy. Through unified collaboration with advocacy groups, medical and research professionals, and pharma/biotech companies, we provide support, networking, and education to help navigate the journey of the disease.
MLD Foundation has been in existence for over 25 years helping support families diagnosed with Metachromatic Leukodystrophy navigate the MLD journey. Our mission is we C.A.R.E. facilitating Compassion, increasing Awareness, influencing Research and promoting Education for Metachromatic Leukodystrophy.
Research
ClinicalTrials.gov for MLD (birth to 17 years)
These are clinical trials that are recruiting or will be recruiting. Updates are made daily, so you are encouraged to check back frequently.
ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world. This is a resource provided by the U.S. National Library of Medicine (NLM), which is an institute within the National Institutes of Health (NIH). Listing a study does not mean it has been evaluated by the U.S. Federal Government. Please read the NLM disclaimer for details.
Before participating in a study, you are encouraged to talk to your health care provider and learn about the risks and potential benefits.
For more information about participation in clinical trials, check out our education hub on the topic here.
The information in the CNF Child Neurology Disorder Directory is not intended to provide diagnosis, treatment, or medical advice and should not be considered a substitute for advice from a healthcare professional. Content provided is for informational purposes only. CNF is not responsible for actions taken based on the information included on this webpage. Please consult with a physician or other healthcare professional regarding any medical or health related diagnosis or treatment options.
References
- Adang LA, Bonkowsky JL, Boelens JJ, Mallack E, Ahrens-Nicklas R, Bernat JA, Bley A, Burton B, Darling A, Eichler F, Eklund E, Emrick L, Escolar M, Fatemi A, Fraser JL, Gaviglio A, Keller S, Patterson MC, Orchard P, Orthmann-Murphy J, Santoro JD, Schöls L, Sevin C, Srivastava IN, Rajan D, Rubin JP, Van Haren K, Wasserstein M, Zerem A, Fumagalli F, Laugwitz L, Vanderver A. Consensus guidelines for the monitoring and management of metachromatic leukodystrophy in the United States. Cytotherapy. 2024 Jul;26(7):739-748. doi: 10.1016/j.jcyt.2024.03.487. Epub 2024 Apr 1. PMID: 38613540; PMCID: PMC11348704.
- Chang SC, Eichinger CS, Field P. The natural history and burden of illness of metachromatic leukodystrophy: a systematic literature review. Eur J Med Res. 2024 Mar 18;29(1):181. doi: 10.1186/s40001-024-01771-1. PMID: 38494502; PMCID: PMC10946116.
- Gritsman D, Gritsman M, Urazova O, et al. Metachromatic Leukodystrophy: Diagnosis, Modeling, and Therapy. Int J Mol Sci. 2020 Oct 20;21(20):7677. doi:10.3390/ijms21207677. PMID: 33092058; PMCID: PMC7606900.1
- Eichler F, Deodato F, Biffi A, et al. Metachromatic leukodystrophy: A story of hope woven from sorrow. Mol Genet Metab. 2024 Apr 16;143(2):107664. doi:10.1016/j.ymgme.2024.107664. PMID: 38624163; PMCID: PMC11081914.2
- Zalc B, Gieselmann V, Aubourg P, et al. Natural history of adult-onset metachromatic leukodystrophy. Brain. 2025 Apr 1;148(4):1157-1170. doi:10.1093/brain/awad091. PMID: 38699999; PMCID: PMC11961487.3
- MedlinePlus Genetics. Metachromatic leukodystrophy. Bethesda (MD): National Library of Medicine (US); 2021 Jun 29. Available from: https://medlineplus.gov/genetics/condition/metachromatic-leukodystrophy/.4
- Eichler FS, Grodd W, Grant E, et al. Metachromatic Leukodystrophy: A Scoring System for Brain MR Severity. AJNR Am J Neuroradiol. 2008 Apr;29(4):725-731. doi:10.3174/ajnr.A0906. PMID: 18272557; PMCID: PMC7051299.5
- Kehrer C, Blumenstock G, Gieselmann V, Krageloh-Mann I. Metachromatic leukodystrophy: Disease spectrum and diagnostic challenges. J Inherit Metab Dis. 2015 Mar;38(2):305-315. doi:10.1007/s10545-014-9774-5. PMID: 25987178.6
- Gieselmann V, Krageloh-Mann I. Metachromatic leukodystrophy--an update. Neuropediatrics. 2010 Feb;41(1):1-6. doi:10.1055/s-0030-1253427. PMID: 20571983.7
- Dvorakova L, Zeman J, Vondrackova A, et al. Metachromatic Leukodystrophy: a Case of Triplets with the Late Infantile Form. Case Rep Neurol. 2014 Jan-Apr;6(1):49-54. doi:10.1159/000360623. PMID: 25317366; PMCID: PMC4301611.
- Perplexity AI, Inc. Perplexity [Internet]. San Francisco (CA): Perplexity AI, Inc.; 2025 [cited 2025 Oct 24]. Available from: https://www.perplexity.ai
This overview is for general information and is not a substitute for advice from your child's care team.
← Back to the Disorder Directory